Saroglitazar safety in moderate liver impairment from cholestatic disease
Treatments studied
Part of Digestive system clinical trials.
This trial tests how the body processes saroglitazar in people with moderate liver impairment caused by cholestatic liver disease. The goal is to ensure the drug is safe and dosed correctly for this group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- Your body mass index (BMI) must be between 18 and 48.
- You must have liver cirrhosis with a Child-Pugh score of 7 to 9, due to cholestatic liver disease.
- Your blood tests must meet specific levels for liver enzymes, blood cells, and other markers.
- You must be able to swallow and keep down oral medication.
- You must agree to follow the study rules and give written permission.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial studies how saroglitazar magnesium works in people with liver scarring (cirrhosis) caused by a bile-flow problem. It helps doctors understand safety and how the body handles the medicine in this specific liver condition.
This trial tests a new oral medication, saroglitazar magnesium, for people with Primary Biliary Cholangitis (PBC) who have not improved enough on standard therapy (UDCA) or cannot tolerate it. The goal is to see if it can help control liver enzymes and improve outcomes.
This study tests a new drug called saroglitazar to see if it can improve long-term outcomes in people with primary biliary cholangitis (PBC) who have cirrhosis. It may be an option if you are already on UDCA or cannot take it, and if your liver function tests meet certain levels.
This trial tests if a medication called Chiglitazar (a type of insulin sensitizer) is safe and effective for people with cirrhosis caused by metabolic-associated fatty liver disease (MAFLD). It may help reduce liver scarring and improve metabolic health.
This trial tests a new oral medication, Chiglitazar, for people who have both type 2 diabetes and a fatty liver condition called MASH (fatty liver with inflammation and scarring). It aims to see if the drug can help improve liver health and diabetes control.
This trial tests whether adding a new diabetes medication called chiglitazar to your current SGLT-2 inhibitor can help lower your blood sugar better. You may qualify if your blood sugar is still too high despite taking an SGLT-2 inhibitor, and this study could help find better ways to control your diabetes.
Hear when a new Cholestatic Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.